May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab (Avastin) in Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • A. Saucedo-Castillo
    Retina and Vitreous, Fundacion Hospital Nuestra Senora de la Luz IAP, Mexico City, Mexico
  • A. Levine-Berebichez
    Retina and Vitreous, Fundacion Hospital Nuestra Senora de la Luz IAP, Mexico City, Mexico
  • S. Rojas-Juarez
    Retina and Vitreous, Fundacion Hospital Nuestra Senora de la Luz IAP, Mexico City, Mexico
  • Footnotes
    Commercial Relationships A. Saucedo-Castillo, None; A. Levine-Berebichez, None; S. Rojas-Juarez, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1429. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Saucedo-Castillo, A. Levine-Berebichez, S. Rojas-Juarez; Intravitreal Bevacizumab (Avastin) in Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1429.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To evaluate the efficacy of intravitreal bevacizumab in patients with Proliferative Diabetic Retinopathy.

Methods:: This is a prospective, experimental, longitudinal and descriptive study. Patients with proliferative diabetic retinopathy with papilar or/and extrapapilar neovascularization without media opacities were included. All patients received 1.8mg (0.07ml) of intravitreal bevacizumab at 3 to 3.5mm from limbus. The patients underwent clinic evaluation with fluorescein angiography control with a minimal follow up of 3 months. In cases where neovascularization persists, conventional photocoagulation was indicated.

Results:: 40 eyes were included. Mean age was 58 years old. 32.5% had rubeosis, 52.5% papilar neovascularization and 65% extrapapilar neovascularization. We found remission of retinal and papillary neovascularization in 75% of cases during the first month. In 25% of cases the neovascularization persisted at one month, 50% had recurrence at two months and 60% at 3 months of follow up. The papilar neovascularization had shown better response than retinal neovascularization. Vascular changes after intravitreal bevaciazumab injection were observed in 15% of cases. Changes in intraocular pressure were not seen after intravitreal injection.

Conclusions:: Bevacizumab induce early remission of neovascularization in patients with proliferative diabetic retinopathy. It could be a therapeutic alternative in these patients as adjunctive treatment of panretinal photocoagulation, reducing the extensive retinal ablation needed to control the proliferative diabetic retinopathy.

Clinical Trial:: Fundacion Hospital Nuestra Senora de la Luz IAP

Keywords: diabetic retinopathy • retinal neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.